Funding vaccines goes far beyond purchasing doses. It involves maintaining cold chains, training healthcare workers, and reaching remote or underserved populations with consistent service. For many low- and middle-income countries, rising costs and reduced donor support have made sustaining these programs increasingly difficult.
This page explores the shifting landscape of immunization financing based on insights from the USAID-supported Partnerships for Health Reform Project. It highlights key issues like cost recovery, government budgeting, donor dependence, and international procurement mechanisms. The goal is to equip stakeholders with clear, actionable information to support long-term, equitable immunization strategies.
Key Concepts in Immunization Financing
Understanding how immunization programs are financed requires more than tracking how much vaccines cost. The following concepts highlight the most critical elements that shape immunization financing across different countries and systems.
1. Comprehensive Cost Scope
Immunization financing includes more than just vaccines. Programs require syringes, cold chain equipment, transport, and outreach. Overlooking these recurring costs results in gaps that directly affect service delivery.
Unfunded elements like supervision, data reporting, and waste management often stretch limited budgets. When these areas are ignored, programs risk underperformance despite having vaccine supply. Comprehensive planning must factor in all operational components to avoid breakdowns in coverage.
2. Evolving Funding Responsibility
Countries are increasingly expected to finance vaccines and operational costs as donor funding declines. This transition has been faster in middle-income countries but remains uneven across regions. Lower-income countries still rely heavily on donor support for logistics and system maintenance.
The introduction of newer, costlier vaccines adds pressure to already constrained budgets. Without clear strategies for domestic funding, coverage and quality may decline over time. Countries must prioritize financing reforms that allow stable co-funding of both vaccines and service delivery infrastructure.
3. Strategic Integration with Health Systems
Decentralization changes how funds are managed, often transferring responsibilities to local governments. In many cases, local capacity does not match these new roles, leading to inefficiencies. Weak coordination between national and subnational levels disrupts planning and oversight.
To avoid fragmented delivery, financing mechanisms must support both autonomy and accountability. Without this balance, routine services face inconsistent coverage and limited sustainability. Strong policy frameworks are needed to guide financing decisions at every level of the health system.
Understanding the Costs of Immunization
Immunization programs face the challenge of accurately calculating their full delivery costs. While vaccine prices are often highlighted, operational expenses like transport, storage, cold chain systems, and personnel are just as critical. In fixed facility settings, the average cost to fully immunize a child with the original six EPI vaccines is about $15, though this varies by country and delivery model.
Newer vaccines such as Hepatitis B and Hib add significantly to overall program costs due to higher prices and expanded logistical needs. These include cold chain upgrades, training, and additional outreach, all of which strain existing health budgets. Nearly half of the countries surveyed by UNICEF couldn’t provide reliable data on total recurrent costs, making it difficult to plan, scale, or secure sustained funding.
International Vaccine Financing Mechanisms
To help countries secure affordable, timely access to vaccines, several global financing tools have been developed. These mechanisms aim to reduce procurement barriers, stabilize supply, and support national budgeting efforts—particularly in low-income settings.
1. PAHO Revolving Fund
Established in 1979, the PAHO Revolving Fund allows Latin American and Caribbean countries to purchase vaccines collectively at negotiated low prices. By pooling demand and using long-term contracts, the fund improves price stability and supply consistency.
Countries participating in the fund can buy vaccines in local currency and pay after delivery, removing major roadblocks like hard currency shortages and upfront payments. Nearly every country in the region uses this system, making it a foundational element in regional vaccine security.
2. UNICEF’s Vaccine Independence Initiative (VII)
Launched in 1991, the Vaccine Independence Initiative creates national revolving funds tied to UNICEF’s procurement platform. Countries can access quality vaccines at low cost with delayed payment options, mirroring PAHO’s approach but tailored to other global regions.
As of the report, 20 countries—including 12 Pacific Island nations—had active VII contracts. While the model helps bridge short-term financing gaps, its long-term sustainability depends on whether countries gradually increase their own financial contributions.
3. European Union Initiative
The EU Initiative, active in eight Sahelian African countries, channels structural adjustment funds into vaccine budgets by creating dedicated immunization line items. It promotes national ownership by embedding vaccines into formal budgeting processes.
Critics argue that this approach may divert funds from other critical health services, especially in the poorest countries. Without strong tracking tools or transition plans, there’s a risk that countries remain dependent on external earmarks without building durable financing structures.
Major Information Gaps Identified
Despite decades of investment in global immunization, key data on program costs, financing models, and operational realities remain incomplete. These gaps limit the ability of governments and partners to plan, budget, and measure the long-term sustainability of immunization programs.
1. Outdated or Incomplete Cost Data
Most cost studies were conducted in the 1980s, with few updated analyses available for modern delivery systems. Without current data, countries can’t accurately estimate the true cost of reaching full coverage—especially with new vaccines added to national schedules.
Critical components like injection safety, cold chain upgrades, and social mobilization often go unmeasured. This lack of granular cost data hinders budget planning and weakens the case for sustained domestic or donor investment.
2. Limited Insight into Financing Transitions
There’s little documentation on how countries are managing the shift from donor to domestic funding. Few studies track what percentage of total program costs are truly financed by governments versus external partners.
Without this visibility, it’s difficult to evaluate financial sustainability or measure progress toward self-reliance. Countries may appear more autonomous on paper than they are in practice.
3. Cost Recovery Outcomes Are Poorly Tracked
While some countries charge user fees for immunization, there’s almost no analysis of who pays, how much is collected, or what impact fees have on service access. The effect of cost recovery on equity, coverage, and program quality is largely unknown.
Data is also lacking on whether alternative financing tools—like prepayment schemes or health insurance—are being used to support immunization delivery. This limits options for countries seeking innovative, context-appropriate funding models.
4. Unclear Role of Private and NGO Sectors
The scale and impact of non-governmental and for-profit providers in vaccine delivery are still poorly documented. Their contributions to financing, access, or efficiency remain anecdotal rather than evidence-based.
Understanding who they serve and how they complement—or compete with—public programs is essential for planning equitable coverage. Without this data, policymakers can’t fully leverage or regulate these partners.
5. Weak Link Between Campaigns and Routine Services
Vertical disease campaigns like polio eradication have both helped and hurt routine immunization programs. However, the net impact is unclear due to a lack of rigorous evaluation.
Better data is needed on how campaign resources can be structured to strengthen, rather than sideline, core services. Otherwise, countries may repeat mistakes that undermine long-term system resilience.
Recommendations and Action Areas
To strengthen immunization financing in low- and middle-income countries, stakeholders need better data, more flexible funding models, and stronger alignment between domestic priorities and global support tools. The following action areas target the most urgent gaps and offer practical steps toward long-term sustainability.
1. Update Costing Frameworks
Countries need updated, standardized methods to track the full cost of immunization programs—including new vaccines, delivery systems, and safety tools. These frameworks should capture real-world expenses beyond vaccine prices, such as training, cold chain logistics, and social mobilization.
Without this data, governments can’t plan budgets effectively or make informed trade-offs. Development partners also need these figures to justify long-term investments and monitor how resources are used.
2. Strengthen Domestic Financing Strategies
National governments must define clear plans for increasing their share of immunization financing. This includes setting targets, formalizing line items, and gradually reducing reliance on donor support for core program costs.
Stable domestic funding is key to program resilience. Countries that commit resources consistently are better positioned to introduce new vaccines, respond to disease threats, and maintain high coverage levels.
3. Expand Evidence on Private and NGO Involvement
Governments should collect data on private and NGO contributions to immunization delivery. This includes coverage statistics, financing inputs, and target populations served.
With better visibility, countries can decide how to integrate these actors into national plans or regulate their operations. Clear data also prevents duplication of services and ensures better use of limited resources.
4. Improve Integration Between Campaigns and Routine Services
Future disease control initiatives must be designed to support—not displace—routine immunization systems. This means using campaign infrastructure for long-term planning, staff training, and public awareness that benefits all vaccines.
Coordination with national EPI programs should be built in from the start. By aligning goals, countries can maximize impact and avoid weakening essential services once campaign funding ends.
5. Enhance Tracking of Financing Mechanisms
Mechanisms like the PAHO Revolving Fund, VII, and the EU Initiative need stronger accountability systems to monitor their impact. Governments should report how much of their vaccine budget is sourced through these tools, and what share comes from domestic funds.
Tracking helps identify where support is working—and where it’s masking structural gaps. It also allows stakeholders to adjust strategies based on actual country performance rather than assumptions.
Conclusion: Toward Smarter, Sustainable Immunization Systems
The long-term success of immunization programs depends not only on vaccine availability but on how effectively those programs are financed, managed, and adapted to changing realities. Countries must take ownership of both the financial and operational aspects of vaccine delivery, supported by transparent data and coordinated global partnerships.
As new vaccines emerge and funding landscapes shift, governments and stakeholders need actionable strategies rooted in evidence, not assumptions. By closing information gaps, strengthening domestic financing, and improving coordination across sectors, countries can build resilient systems that protect health for generations to come.